Developer docs
API playgroundTry for free, no card

Search company profiles

Banner Life Sciences

Full company profile

uuid000c348

Namestring
Banner Life Sciences
Legal namestring
Banner Life Sciences LLC
Websiteurl
bannerls.com
Company typeenum
Private
Founded yearstring
-
Descriptiontext

Banner Life Sciences is a privately held specialty pharmaceutical company headquartered in High Point, North Carolina, that develops and commercializes therapeutics for patients with unmet clinical needs. Its sole commercial product is BAFIERTAM (monomethyl fumarate) delayed-release capsules, an oral disease-modifying therapy approved by the FDA on April 30, 2020 for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. BAFIERTAM was developed under the FDA's 505(b)(2) pathway and is positioned as a bioequivalent alternative to Biogen's Tecfidera (dimethyl fumarate), leveraging proprietary formulation technology that delivers monomethyl fumarate directly without requiring metabolic conversion and supports claims of no dietary restrictions and potentially improved gastrointestinal tolerability versus Tecfidera.

Short descriptiontext

Banner Life Sciences is a U.S. specialty pharmaceutical company that develops and commercializes BAFIERTAM, an FDA-approved oral disease-modifying therapy for relapsing forms of multiple sclerosis, now operating as a subsidiary of UK-based Cycle Pharmaceuticals.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHigh Point, United States
HQ citystring
High Point
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceuticals, multiple sclerosis therapy, oral MS treatment, neurology drug development, delayed-release formulations
Industry2 codes
PRIMARYHLAGAFAL
Formulation & Preclinical CMC Support (Nonclinical)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Scientific Research and Development Services5417
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Specialty Pharmaceuticals (Multiple Sclerosis Therapeutics)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical product sales
TypeOthers
Description

Banner Life Sciences generates revenue through the sale of BAFIERTAM (monomethyl fumarate), a prescription disease-modifying therapy for relapsing forms of multiple sclerosis. BAFIERTAM was granted final FDA approval on April 30, 2020, enabling commercial sales in the U.S. market. The product competes as a bioequivalent alternative to Biogen's Tecfidera.

openpr.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Operations
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1BAFIERTAM®
Description

Monomethyl fumarate delayed-release capsules - a disease-modifying therapy (DMT) for the treatment of relapsing forms of multiple sclerosis. Bioequivalent alternative to Biogen's Tecfidera®.

bannerls.com
Core offering1 text field

Banner Life Sciences combines formulation expertise with proprietary technologies to develop and commercialize specialty pharmaceuticals for patients with unmet clinical needs. Its flagship product, BAFIERTAM (monomethyl fumarate) delayed-release capsules, is an FDA-approved oral disease-modifying therapy for relapsing forms of multiple sclerosis, positioned as a bioequivalent alternative to Biogen's Tecfidera (dimethyl fumarate) at a lower dose with potentially improved gastrointestinal tolerability. The product is dispensed through U.S. specialty and retail pharmacies and supported by the Cycle Vita patient support program.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Lower dose of BAFIERTAM is equivalent to Tecfidera and may improve gastrointestinal tolerability for patients, especially early in treatment.
Product overview1 text field

Banner Life Sciences is a specialty pharmaceutical company that develops and commercializes specialty pharmaceuticals for patients with unmet clinical needs. The company operates as a Cycle Pharmaceuticals company and its core product portfolio includes BAFIERTAM (monomethyl fumarate), an oral disease-modifying therapy for relapsing forms of multiple sclerosis. Patient support is delivered through Cycle Vita, which provides individualized support services for MS patients. Additionally, Cycle offers TASCENSO ODT (fingolimod) as another oral MS medication under the Cycle Vita support program.

Product and service2 records
1BAFIERTAM (monomethyl fumarate) delayed-release capsules
CategoryPrescription specialty pharmaceutical
Description

An oral disease-modifying therapy (DMT) for relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. It is a bioequivalent alternative to Biogen's Tecfidera (dimethyl fumarate) that requires no dietary restrictions and no metabolic conversion.

2Cycle Vita Patient Support for BAFIERTAM
CategoryPatient support service
Description

Patient support program providing individualized financial, product, process, and clinical support to eligible patients starting BAFIERTAM therapy, including a dedicated MS support line and a team of Clinical Education Managers.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Cycle Vita
Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2025-03-31
Description

Cycle Vita expanded its patient support services in Multiple Sclerosis to include BAFIERTAM from April 1, 2025. Cycle Vita provides individualized financial, product, process and clinical support to eligible patients. New patients starting BAFIERTAM from April 2025 onwards are supported by Cycle Vita. Existing patients are being migrated from Banner Patient Support to Cycle Vita in partnership with their healthcare providers. Cycle Vita's MS-dedicated support services and team of Clinical Education Managers are now available to BAFIERTAM patients.

bannerls.com
Strategic tierMinorTypeOthersAnnounced on2020-04-30
Description

Biogen Inc. is the maker of Tecfidera (dimethyl fumarate), to which BAFIERTAM (monomethyl fumarate) is bioequivalent. Banner Life Sciences engaged in patent litigation with Biogen regarding U.S. Patent Number 7,619,001 ('the '001 patent'). The U.S. District Court for the District of Delaware ruled in favor of Banner in January 2019, and the U.S. Court of Appeals for the Federal Circuit upheld this decision on April 21, 2020, confirming BAFIERTAM does not infringe the '001 patent.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Markets Aubagio (teriflunomide), an oral DMT for relapsing MS. Sanofi is a direct competitor in the oral disease-modifying therapy category alongside BAFIERTAM.

TypeDirect peer
Description

Markets Gilenya (fingolimod), Kesimpta (ofatumumab), and Mayzent (siponimod) for MS — covering both oral and high-efficacy injectable options in the same relapsing MS patient population Banner targets.

TypeBroad incumbent
Description

Markets Ocrevus (ocrelizumab), the leading high-efficacy anti-CD20 therapy for relapsing and primary progressive MS. Roche's commercial reach and clinical profile anchor the treatment paradigm Banner competes within.

TypeDirect peer
Description

Innovator of Tecfidera (dimethyl fumarate), the reference product to which BAFIERTAM is a bioequivalent. Biogen is the most direct competitor in the U.S. relapsing MS oral fumarate market and the party Banner litigated against in the '001 patent case.

TypeEmerging player
Description

Smaller specialty pharma developing Briumvi (ublituximab) for relapsing MS. Comparable as an emerging competitor pursuing differentiated MS therapies against larger incumbents.

TypeDirect peer
Description

Markets Mavenclad (cladribine), an oral high-efficacy DMT for relapsing MS, placing Merck KGaA in direct competition with BAFIERTAM for oral RRMS prescriptions.

TypeBroad incumbent
Description

Large generics and specialty manufacturer with broad MS-related product exposure, including authorized generic Tecfidera. Comparable as the kind of low-cost generic competitor that frames BAFIERTAM's commercial pricing pressure.

TypeBroad incumbent
Description

Markets Copaxone (glatiramer acetate), one of the legacy injectable DMTs in MS, and is a broad neurology/specialty pharma incumbent. Comparable as a long-standing specialty pharma player in the MS DMT market.

9Bristol Myers Squibb
TypeDirect peer
Description

Markets Zeposia (ozanimod), an oral S1P modulator approved for relapsing forms of MS. BMS competes head-to-head with BAFIERTAM for neurologist prescriptions in the oral DMT category.

TypeEmerging player
Description

Israeli specialty pharma developing long-acting glatiramer acetate (GA Depot) for MS, with a 505(b)(2)-style reformulation approach. Comparable as a smaller specialty player pursuing differentiated, longer-acting formulations in the same indication.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Banner Life Sciences

Specialty Pharmaceuticals (Multiple Sclerosis Therapeutics)bannerls.com

Banner Life Sciences is a U.S. specialty pharmaceutical company that develops and commercializes BAFIERTAM, an FDA-approved oral disease-modifying therapy for relapsing forms of multiple sclerosis, now operating as a subsidiary of UK-based Cycle Pharmaceuticals.

What Banner Life Sciences does

Banner Life Sciences is a privately held specialty pharmaceutical company headquartered in High Point, North Carolina, that develops and commercializes therapeutics for patients with unmet clinical needs. Its sole commercial product is BAFIERTAM (monomethyl fumarate) delayed-release capsules, an oral disease-modifying therapy approved by the FDA on April 30, 2020 for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. BAFIERTAM was developed under the FDA's 505(b)(2) pathway and is positioned as a bioequivalent alternative to Biogen's Tecfidera (dimethyl fumarate), leveraging proprietary formulation technology that delivers monomethyl fumarate directly without requiring metabolic conversion and supports claims of no dietary restrictions and potentially improved gastrointestinal tolerability versus Tecfidera.

Banner Life Sciences firmographics

Firmographics
Name
Banner Life Sciences
Legal name
Banner Life Sciences LLC
Website
https://bannerls.com
Company type
Private
Operating status
Operating
Headcount range
11–50 employees
Short description
Banner Life Sciences is a U.S. specialty pharmaceutical company that develops and commercializes BAFIERTAM, an FDA-approved oral disease-modifying therapy for relapsing forms of multiple sclerosis, now operating as a subsidiary of UK-based Cycle Pharmaceuticals.
Ownership category
akta.pro rank

Banner Life Sciences industry classification

Industry
Product category
Specialty Pharmaceuticals (Multiple Sclerosis Therapeutics)
NAICS
Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAFAL
Formulation & Preclinical CMC Support (Nonclinical)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Specialty pharmaceuticals
  • Multiple sclerosis therapy
  • Oral MS treatment
  • Neurology drug development
  • Delayed-release formulations

Where Banner Life Sciences is headquartered

Location

Headquarters

HQ city
High Point
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Banner Life Sciences business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Operations

Revenue model

  1. Pharmaceutical product sales: Banner Life Sciences generates revenue through the sale of BAFIERTAM (monomethyl fumarate), a prescription disease-modifying therapy for relapsing forms of multiple sclerosis. BAFIERTAM was granted final FDA approval on April 30, 2020, enabling commercial sales in the U.S. market. The product competes as a bioequivalent alternative to Biogen's Tecfidera.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Banner Life Sciences product offering

Product offering

Core offering

Banner Life Sciences combines formulation expertise with proprietary technologies to develop and commercialize specialty pharmaceuticals for patients with unmet clinical needs. Its flagship product, BAFIERTAM (monomethyl fumarate) delayed-release capsules, is an FDA-approved oral disease-modifying therapy for relapsing forms of multiple sclerosis, positioned as a bioequivalent alternative to Biogen's Tecfidera (dimethyl fumarate) at a lower dose with potentially improved gastrointestinal tolerability. The product is dispensed through U.S. specialty and retail pharmacies and supported by the Cycle Vita patient support program.

Product overview

Banner Life Sciences is a specialty pharmaceutical company that develops and commercializes specialty pharmaceuticals for patients with unmet clinical needs. The company operates as a Cycle Pharmaceuticals company and its core product portfolio includes BAFIERTAM (monomethyl fumarate), an oral disease-modifying therapy for relapsing forms of multiple sclerosis. Patient support is delivered through Cycle Vita, which provides individualized support services for MS patients. Additionally, Cycle offers TASCENSO ODT (fingolimod) as another oral MS medication under the Cycle Vita support program.

Differentiator

Problem solved

Functional benefit

Brands

  • BAFIERTAM®: Monomethyl fumarate delayed-release capsules - a disease-modifying therapy (DMT) for the treatment of relapsing forms of multiple sclerosis. Bioequivalent alternative to Biogen's Tecfidera®.

Products and services

  • BAFIERTAM (monomethyl fumarate) delayed-release capsules An oral disease-modifying therapy (DMT) for relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. It is a bioequivalent alternative to Biogen's Tecfidera (dimethyl fumarate) that requires no dietary restrictions and no metabolic conversion.
  • Cycle Vita Patient Support for BAFIERTAM Patient support program providing individualized financial, product, process, and clinical support to eligible patients starting BAFIERTAM therapy, including a dedicated MS support line and a team of Clinical Education Managers.

Quantifiable outcome

  • Lower dose of BAFIERTAM is equivalent to Tecfidera and may improve gastrointestinal tolerability for patients, especially early in treatment.

Companies that use Banner Life Sciences

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Banner Life Sciences technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Banner Life Sciences partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and minor.

  • Cycle VitacoreGTM or Marketing Partner · 31 March 2025Cycle Vita expanded its patient support services in Multiple Sclerosis to include BAFIERTAM from April 1, 2025. Cycle Vita provides individualized financial, product, process and clinical support to eligible patients. New patients starting BAFIERTAM from April 2025 onwards are supported by Cycle Vita. Existing patients are being migrated from Banner Patient Support to Cycle Vita in partnership with their healthcare providers. Cycle Vita's MS-dedicated support services and team of Clinical Education Managers are now available to BAFIERTAM patients.
  • Biogen Inc.minorOthers · 30 April 2020Biogen Inc. is the maker of Tecfidera (dimethyl fumarate), to which BAFIERTAM (monomethyl fumarate) is bioequivalent. Banner Life Sciences engaged in patent litigation with Biogen regarding U.S. Patent Number 7,619,001 ('the '001 patent'). The U.S. District Court for the District of Delaware ruled in favor of Banner in January 2019, and the U.S. Court of Appeals for the Federal Circuit upheld this decision on April 21, 2020, confirming BAFIERTAM does not infringe the '001 patent.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Banner Life Sciences competitors and assessment

Company assessment

Direct peers

  • Sanofi: Markets Aubagio (teriflunomide), an oral DMT for relapsing MS. Sanofi is a direct competitor in the oral disease-modifying therapy category alongside BAFIERTAM.
  • Novartis: Markets Gilenya (fingolimod), Kesimpta (ofatumumab), and Mayzent (siponimod) for MS — covering both oral and high-efficacy injectable options in the same relapsing MS patient population Banner targets.
  • Biogen: Innovator of Tecfidera (dimethyl fumarate), the reference product to which BAFIERTAM is a bioequivalent. Biogen is the most direct competitor in the U.S. relapsing MS oral fumarate market and the party Banner litigated against in the '001 patent case.
  • Merck KGaA: Markets Mavenclad (cladribine), an oral high-efficacy DMT for relapsing MS, placing Merck KGaA in direct competition with BAFIERTAM for oral RRMS prescriptions.
  • Bristol Myers Squibb: Markets Zeposia (ozanimod), an oral S1P modulator approved for relapsing forms of MS. BMS competes head-to-head with BAFIERTAM for neurologist prescriptions in the oral DMT category.

Broad incumbents

  • Roche: Markets Ocrevus (ocrelizumab), the leading high-efficacy anti-CD20 therapy for relapsing and primary progressive MS. Roche's commercial reach and clinical profile anchor the treatment paradigm Banner competes within.
  • Viatris: Large generics and specialty manufacturer with broad MS-related product exposure, including authorized generic Tecfidera. Comparable as the kind of low-cost generic competitor that frames BAFIERTAM's commercial pricing pressure.
  • Teva Pharmaceutical Industries: Markets Copaxone (glatiramer acetate), one of the legacy injectable DMTs in MS, and is a broad neurology/specialty pharma incumbent. Comparable as a long-standing specialty pharma player in the MS DMT market.

Emerging players

  • TG Therapeutics: Smaller specialty pharma developing Briumvi (ublituximab) for relapsing MS. Comparable as an emerging competitor pursuing differentiated MS therapies against larger incumbents.
  • Mapi Pharma: Israeli specialty pharma developing long-acting glatiramer acetate (GA Depot) for MS, with a 505(b)(2)-style reformulation approach. Comparable as a smaller specialty player pursuing differentiated, longer-acting formulations in the same indication.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Banner Life Sciences social profiles

Digital presence

Banner Life Sciences compliance and trust

Trust signal

Compliance2 records

Banner Life Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Banner Life Sciences leadership team

Management profile

Number of profiles

Profiles1 record

Banner Life Sciences funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Banner Life Sciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Banner Life Sciences

What does Banner Life Sciences do?

Banner Life Sciences combines formulation expertise with proprietary technologies to develop and commercialize specialty pharmaceuticals for patients with unmet clinical needs. Its flagship product, BAFIERTAM (monomethyl fumarate) delayed-release capsules, is an FDA-approved oral disease-modifying therapy for relapsing forms of multiple sclerosis, positioned as a bioequivalent alternative to Biogen's Tecfidera (dimethyl fumarate) at a lower dose with potentially improved gastrointestinal tolerability. The product is dispensed through U.S. specialty and retail pharmacies and supported by the Cycle Vita patient support program.

Is Banner Life Sciences a public or private company?

Banner Life Sciences is a private company. It is classified as corporate owned and is currently operating.

When was Banner Life Sciences founded?

Banner Life Sciences was founded in -1. It employs 11 to 50 people.

Where is Banner Life Sciences based?

Banner Life Sciences is headquartered in High Point, United States, in the North America region.

How does Banner Life Sciences make money?

One revenue line is on record: pharmaceutical product sales.

Who are Banner Life Sciences's main competitors?

Direct peers on record are Sanofi, Novartis, Biogen, Merck KGaA and Bristol Myers Squibb. Broad incumbents are Roche, Viatris and Teva Pharmaceutical Industries. Emerging players are TG Therapeutics and Mapi Pharma.

Does Banner Life Sciences have an API?

No public API is recorded for Banner Life Sciences.

What industry is Banner Life Sciences in?

Banner Life Sciences's product category is Specialty Pharmaceuticals (Multiple Sclerosis Therapeutics). Its primary akta.pro industry code is HLAGAFAL, Formulation & Preclinical CMC Support (Nonclinical), with a secondary code of HLAGAHAM, Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals